For how we live.
Before October 2023, Palestinian health authorities had documented 50 people living with HIV in Gaza. A viewpoint argues the collapse of testing and treatment has since erased that count entirely.
Seventy-seven thousand fewer children got PEPFAR-supported HIV treatment in 2025 than the year before. UNAIDS warns permanent cuts could mean millions of additional infections and deaths by 2029.
In women 41 to 50, late perimenopause and postmenopause brought measurable declines in lung volume, with postmenopausal women losing up to 310 mL of FEV1. HIV status didn't change the pattern.
Washington intends to provide up to $792 million over five years. Malawi commits the rest — and the money is meant to flow through the government rather than NGOs.
Among 1,000 adults in Mwanza, overnight oximetry found sleep apnea in 17% of people with HIV and 19% without. Excessive daytime sleepiness, oddly, was more common in those without HIV.
The modelling study puts 719,384 people on PEPFAR-funded oral PrEP in 28 African countries at the end of 2024. Most projected infections fall on key populations whose coverage was already under 6%.
The recommendation covers people weighing at least 35 kg and rests on two trials in which lenacapavir cut HIV infections by 100% and 96% against background incidence.
Across 165 clinics in four African countries, HIV testing fell by up to 35% and treatment starts by up to 32%. Most services had not returned to baseline two months after the orders were lifted.
IHME's annual accounting puts development assistance for health at less than half its 2021 peak, with no recovery forecast to 2030. A companion model estimates what that means for tuberculosis.
The guidelines pair the new injectable with a second, quieter recommendation: use simplified rapid diagnostic testing to start and continue long-acting PrEP, rather than more complex assays.
Lenacapavir is the first HIV pre-exposure prophylaxis given every six months. Two phase 3 trials found zero and two infections in the lenacapavir groups against background rates above 2 per 100 person-years.